Sees Q3 Core business revenue of $6.4 – 6.6M in the third quarter of 2023, a decrease of 33 – 35% compared to the third quarter of 2022.; strategic Partnership License -related revenue of $1.4M in the third quarter of 2023, compared to $0.8M in the third quarter of 2022
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MXCT:
- MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
- MaxCyte appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
- MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
- MaxCyte to Participate in Baird Global Healthcare Conference
- MaxCyte sees FY23 core revenue comparable to 2022